Zacks Investment Research
28 Sept 2026, 16:46 UTC · 1h ago
Verdict
Headline leans bullish. We score ANIP −0.40 across three claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.40moderately bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
The Zacks Consensus Estimate for ANI Pharmaceuticals for the current quarter decreased from $2.41 to $2.12 over the last 60 days.
Priced intrend over the last 60 days
So whatThis represents a 12% reduction in projected quarterly EPS, likely pressuring the stock's valuation multiple.
More negative than 85% of claims this week
ANI Pharmaceuticals is currently a Zacks Rank #3 (Hold) in an industry ranking in the Bottom 29% of all industries.
Continue reading
5 related stories
More negative than 69% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced instanding Zacks Rank and Industry Rank
More negative than 69% of claims this week
The Oct. 16, 2026 $40.00 Put for ANI Pharmaceuticals exhibited some of the highest implied volatility of all equity options today.
Newstated as occurring "today", Sep 28
Near neutral — 99% of claims this week are stronger
Which stocks this story touches
More negative than 69% of ticker scores this week
The company has a Zacks Rank #3 (Hold), is in a bottom-tier industry rank, and has seen three downward earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
ANIP hasn't traded since this ran. Last close $73.38 (Sep 28); the reaction starts at the next open.
ANIP chart →
